In this episode of 'Conversations in Lung Cancer Research,' host Dr. Rebecca Tay and fellow oncologists A/Prof Surein Arulananda and Dr. Dasantha Jayamanne (DJ) delve into the latest advances in small cell lung cancer treatment.

They explore new first-line treatments, including checkpoint inhibitors and emerging novel agents like lurbinectedin and tarlatamab, highlighting their mechanisms, survival benefits, and toxicity management. The panel also discusses the evolving role of radiotherapy and future directions involving precision medicine and biomarkers. This comprehensive discussion aims to inform clinicians and healthcare professionals about the promising advancements reshaping the small cell lung cancer treatment landscape.

This episode is sponsored by Roche.

TOGA's SCLC Masterclass will take place 20 March 2026, at Novotel on Collins, Melbourne
An advanced workshop covering evolving standards of care and new therapies in SCLC.
Early bird tickets available until 16 Feb 2026 > https://thoraciconcology.org.au/events/masterclass-small-cell-lung-cancer/

RESOURCES AND LINKS:
CREST trial https://pmc.ncbi.nlm.nih.gov/articles/PMC3058352/

Caspian Study https://www.sciencedirect.com/science/article/pii/S1525730425001640

CHEST RT https://trog.com.au/trials/trog-20-01-chest-rt/

DeLLphi-303 https://www.annalsofoncology.org/article/S0923-7534(25)04288-7/fulltext

IMforte https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.8006

Japan study PCI vs MRIhttps://pubmed.ncbi.nlm.nih.gov/28343976/

TIMESTAMPS:

(00:00) Introduction and Acknowledgements

(00:36) Overview of Small Cell Lung Cancer

(02:03) Current First-Line Treatments

(06:59) Radiotherapy in Small Cell Lung Cancer

(11:36) New Developments in Maintenance and Second-Line Treatments

(15:35) Exciting New Therapies and Future Directions

(24:01) Radiotherapy and Immune Engaging Therapies

(32:53) Conclusion and Future Events

KEYWORDS: SCLC, ES-SCLC, Small Cell Lung Cancer, Early Stage Small Cell Lung Cancer